S100A12

If you have months of abdominal pain and loose stools, the question that matters is whether the bowel wall is inflamed or whether the gut is misfiring without tissue inflammation. Those two situations can look the same from the outside. They lead to different care.

S100A12 is an emerging stool marker that helps answer that question. It is less standardized than fecal calprotectin, and it does not replace endoscopy when disease needs to be confirmed. Its value is that it asks a narrower question.

What the Test Measures

S100A12 is a small immune protein stored inside neutrophils. Neutrophils are white blood cells sent early to damaged or infected tissue.

When neutrophils move into the bowel wall and activate, they release S100A12 into the gut. Some of it ends up in stool. That is why a stool result is best read as a signal of neutrophil-driven bowel inflammation, not as a diagnosis by itself.

Calprotectin is the stool inflammation test most people know. It is made by neutrophils, but also by other immune cells and gut-lining cells. S100A12 is much more restricted to granulocytes, the white-cell family that includes neutrophils. The two are different proteins, and lab methods for S100A12 do not cross-react with calprotectin.

That narrower source is the appeal. Calprotectin asks whether gut inflammation is present. S100A12 asks whether neutrophils are a main part of it.

Inflammatory Bowel Disease Versus IBS

This is where the evidence is strongest. In a study of 171 symptomatic adults and 24 healthy controls, stool S100A12 separated active inflammatory bowel disease from irritable bowel syndrome correctly in 86 out of 100 people with the disease, and correctly cleared 96 out of 100 people who had irritable bowel syndrome instead. Against healthy controls, specificity was 100%.

A smaller adult study of 60 people found a similar pattern, catching 97 out of 100 cases with 94 out of 100 correctly cleared. In 337 children with abdominal pain and diarrhea, S100A12 correctly cleared 97 out of 100 who did not have inflammatory bowel disease, compared with 71 out of 100 for calprotectin in the same children.

The practical difference is false alarms. In these studies, S100A12 was less likely than calprotectin to be raised in people who did not have inflammatory bowel disease. That can matter when the alternative is an endoscopy that comes back clean.

Bacterial Versus Viral Diarrhea

Stool S100A12 rose during acute bacterial gut infection and stayed low in viral gastroenteritis in the adult diagnostic study. The reason is simple: bacterial infection often pulls neutrophils into the bowel wall. Most viral gastroenteritis does not do that in the same way.

That is useful and easy to misuse. A high result during a bout of diarrhea does not diagnose inflammatory bowel disease. It may be measuring the infection. If you test while sick, repeat after recovery before treating the result as a chronic inflammation signal.

Watching for a Flare

In people with inflammatory bowel disease in remission, the marker can rise before symptoms return. In a study of 147 adults and 34 children followed over time, stool S100A12 started rising as much as six months before clinical relapse.

At the cutoff the researchers used, the test flagged 70 out of 100 people who later relapsed and correctly reassured 83 out of 100 who stayed well, typically 8 to 12 weeks before symptoms appeared. Higher baseline values were also linked with recurrence during follow-up.

Seventy out of a hundred is not a perfect catch rate. A low result is not permission to ignore new symptoms. But a rising trend can give you time to check drug levels, repeat stool markers, and make treatment decisions before the flare is obvious.

Tracking Response and Bowel-Lining Healing

S100A12 is usually lower when neutrophil-driven inflammation has settled. In children with Crohn's disease, fecal levels fell during therapy in those entering remission. In the ImageKids Crohn's cohort, S100A12 identified healed bowel lining with the same sensitivity as calprotectin and better specificity.

Calprotectin still had the strongest overall link with disease activity in that study. That is the pattern across much of the literature: S100A12 can be more specific, while calprotectin is more established and often more sensitive.

Treatment-response evidence differs depending on whether the marker was measured in blood or in stool. In one 32-person study of anti-TNF therapy in Crohn's disease, blood S100A12 and fecal calprotectin fell in responders, but fecal S100A12 did not fall significantly. Blood S100A12 is a related but different measurement, so it should not be used as proof that this stool test moved.

Where the Test Performs Poorly

After bowel resection for Crohn's disease, S100A12 caught 91 out of 100 endoscopic recurrences but correctly cleared only 12 out of 100 people without recurrence. It flagged almost everyone. In that setting, calprotectin performed better.

The test also performs poorly when the question is isolated small-bowel Crohn's disease. In a capsule endoscopy study, fecal S100A12 could not reliably screen for or exclude small-bowel inflammation.

Very-low-birth-weight infants are another poor fit. Levels rose with intestinal distress, but healthy and distressed infants overlapped too much for the result to guide decisions on its own.

Why One Reading Is Not Enough

The biggest limitation is standardization. Different studies use different lab methods and different cutoffs. S100A12 is still a research-grade or emerging marker in many settings, while calprotectin has wider clinical adoption.

That means your absolute number is less useful than your direction of travel. A single reading, interpreted against a cutoff from a different lab method, can mislead you. A trend from the same lab is more meaningful.

When Results Can Be Misleading

• Recent bacterial gut infection: a bacterial gut infection can raise stool S100A12 sharply. Testing during or soon after infectious diarrhea can make an infection look like chronic bowel inflammation.
• Assay differences between labs: lab methods are not standardized. A number from one lab should not be read against a cutoff from another method.
• Disease limited to the small bowel: isolated small-bowel Crohn's disease can produce a weaker stool signal, so a low result is less reassuring in that setting.
• Recent bowel surgery: after resection for Crohn's disease, the test may flag people with and without recurrence, which makes a high result hard to interpret.
• Blood-versus-stool evidence: serum S100A12 is a different test. Evidence about blood S100A12 should not be applied to stool S100A12 unless the study measured both.